{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:27:39Z","timestamp":1779290859390,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019287","name":"Barts Health NHS Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019287","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.clgc.2025.102468","type":"journal-article","created":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T05:56:10Z","timestamp":1763272570000},"page":"102468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["GAMMA: Results from a Phase II Study for Relapsed Germ Cell Tumors using an Oxaliplatin-Based Treatment Regimen"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9132-4075","authenticated-orcid":false,"given":"Kenrick","family":"Ng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garima","family":"Priyadarshini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Prendergast","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8583-1695","authenticated-orcid":false,"given":"Charlotte","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Rudman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1216-8823","authenticated-orcid":false,"given":"Han Hsi","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantine","family":"Alifrangis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3096-5842","authenticated-orcid":false,"given":"Daniel","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel M.","family":"Berney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Nowosinska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Shamash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.clgc.2025.102468_bib0001","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1200\/JCO.20.03296","article-title":"Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG Update Consortium","volume":"39","author":"Gillessen","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102468_bib0002","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/sj.bjc.6602682","article-title":"A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial","volume":"93","author":"Mead","year":"2005","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.clgc.2025.102468_bib0003","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1200\/JCO.1997.15.4.1427","article-title":"Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma","volume":"15","author":"Miller","year":"1997","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clgc.2025.102468_bib0004","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0006-2952(97)81490-6","article-title":"Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen Panel","volume":"52","author":"Rixe","year":"1996","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102468_bib0005","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s002800100363","article-title":"In vitro studies on the mechanisms of oxaliplatin resistance","volume":"48","author":"Hector","year":"2001","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102468_bib0006","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/annonc\/mdf048","article-title":"Long-term renal function after treatment for malignant germ-cell tumours","volume":"13","author":"Fossa","year":"2002","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.clgc.2025.102468_bib0007","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1200\/JCO.2016.66.8822","article-title":"Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer","volume":"34","author":"Frisina","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2025.102468_bib0008","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/bju.14947","article-title":"Dose-dense chemotherapy for untreated poor-prognosis and relapsed germ-cell tumours: an 18-year experience with GAMEC chemotherapy","volume":"125","author":"Shamash","year":"2020","journal-title":"BJU Int"},{"issue":"8","key":"10.1016\/j.clgc.2025.102468_bib0009","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1200\/JCO.2002.08.050","article-title":"Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group","volume":"20","author":"Kollmannsberger","year":"2002","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2025.102468_bib0010","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1093\/annonc\/mdn122","article-title":"A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors","volume":"19","author":"Theodore","year":"2008","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102468_bib0011","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/bju.13004","article-title":"The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours with high-dose chemotherapy as consolidation: a non-cisplatin-based induction approach","volume":"117","author":"Badreldin","year":"2016","journal-title":"BJU Int"},{"issue":"13","key":"10.1016\/j.clgc.2025.102468_bib0012","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/S1470-2045(14)70490-5","article-title":"Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial","volume":"15","author":"Fizazi","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102468_bib0013","first-page":"76","article-title":"Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker]","volume":"176","author":"Pfannenberg","year":"2004","journal-title":"Rofo"},{"key":"10.1016\/j.clgc.2025.102468_bib0014","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2019.04.013","article-title":"A phase II study of carboplatin AUC-10 guided by positron emission tomography-defined metabolic response in metastatic seminoma","volume":"115","author":"Shamash","year":"2019","journal-title":"Eur J Cancer"},{"issue":"33","key":"10.1016\/j.clgc.2025.102468_bib0015","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1200\/JCO.2009.26.8128","article-title":"Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy","volume":"28","author":"Lorch","year":"2010","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clgc.2025.102468_bib0016","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00259-017-3690-8","article-title":"FDG PET for therapy monitoring in hodgkin and non-hodgkin lymphomas","volume":"44","author":"Barrington","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.clgc.2025.102468_bib0017","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/(SICI)1097-0215(19991210)83:6<831::AID-IJC24>3.0.CO;2-O","article-title":"Management of intermediate-prognosis germ-cell cancer: results of a phase I\/II study of Taxol-BEP","volume":"83","author":"de Wit","year":"1999","journal-title":"Int J Cancer"},{"issue":"12","key":"10.1016\/j.clgc.2025.102468_bib0018","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1200\/JCO.2000.18.12.2413","article-title":"Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer","volume":"18","author":"Motzer","year":"2000","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.clgc.2025.102468_bib0019","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1200\/JCO.2005.19.638","article-title":"Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors","volume":"23","author":"Kondagunta","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102468_bib0020","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.eururo.2006.05.011","article-title":"Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor","volume":"50","author":"De Giorgi","year":"2006","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102468_bib0021","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.eururo.2004.03.001","article-title":"Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study","volume":"46","author":"Pectasides","year":"2004","journal-title":"Eur Urol"},{"issue":"26","key":"10.1016\/j.clgc.2025.102468_bib0022","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1200\/JCO.23.02542","article-title":"Paclitaxel, ifosfamide, and cisplatin as initial salvage chemotherapy for germ cell tumors: long-term follow-up and outcomes for favorable- and unfavorable-risk disease","volume":"42","author":"Gleeson","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T12:10:00Z","timestamp":1768911000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325001685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1558767325001685"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102468","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GAMMA: Results from a Phase II Study for Relapsed Germ Cell Tumors using an Oxaliplatin-Based Treatment Regimen","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102468","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102468"}}